Insider · CIK 0001598502
Karen Jean Ferrante
Files at MGNX (MACROGENICS INC), COGT (Cogent Biosciences, Inc.). First filing -, latest -.
In brief
Karen Jean Ferrante files SEC Form 4 as director at MGNX (MACROGENICS INC), and also at COGT (Cogent Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Karen Jean Ferrante has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +759 | $0.00 | $0 | 759 | 8 d ago |
| Jul 1, 2026 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +627 | $0.00 | $0 | 627 | Jul 6, 2026 |
| Jun 9, 2026 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,901 | $0.00 | $0 | 17,901 | Jun 11, 2026 |
| May 18, 2026 | MGNX MACROGENICS INC | MOption exercise Common Stock | +3,750 | - | - | 14,750 | May 20, 2026 |
| May 18, 2026 | MGNX MACROGENICS INC | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 19, 2026 | MGNX MACROGENICS INC | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | MGNX MACROGENICS INC | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| Apr 1, 2026 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +686 | $0.00 | $0 | 686 | Apr 3, 2026 |
| Jan 1, 2026 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +643 | $0.00 | $0 | 643 | Jan 5, 2026 |
| Oct 1, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,642 | $0.00 | $0 | 1,642 | Oct 3, 2025 |
| Jul 1, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,314 | $0.00 | $0 | 3,314 | Jul 2, 2025 |
| Jun 4, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +44,700 | $0.00 | $0 | 44,700 | Jun 5, 2025 |
| May 20, 2025 | MGNX MACROGENICS INC | MOption exercise Common Stock | +6,500 | - | - | 11,000 | May 22, 2025 |
| May 20, 2025 | MGNX MACROGENICS INC | MOption exercise Restricted Stock Unitderivative | -6,500 | $0.00 | $0 | 0 | May 22, 2025 |
| May 21, 2025 | MGNX MACROGENICS INC | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 22, 2025 |
| May 21, 2025 | MGNX MACROGENICS INC | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 22, 2025 |
| Apr 1, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,788 | $0.00 | $0 | 3,788 | Apr 3, 2025 |
| Jan 1, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +2,785 | $0.00 | $0 | 2,785 | Jan 3, 2025 |
Questions about Karen Jean Ferrante
Answered from the filings on this page, as of the latest one.
Is Karen Jean Ferrante buying or selling?
Karen Jean Ferrante has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Karen Jean Ferrante's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Karen Jean Ferrante has 0.
Where does Karen Jean Ferrante file Form 4?
Karen Jean Ferrante has filed Form 4 at MGNX (MACROGENICS INC); COGT (Cogent Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.